A comprehensive 2026 guide to UK online casinos with a 400% bonus. Understand wagering, find the best offers, and see if a 4x match is actually worth it. Read our full guide to 400% casino bonuses
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project
The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia. German independent research…
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis. XSeed Labs – a…
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy. BioMed X, a German biomedical research…
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Researchers at the BioMed X Institute and the Universit?tsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances. BioMed…
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development BioMed X, a German independent research institute, announces the start of…
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the…
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers. BioMed X, an independent biomedical…